Biomedical start-ups benefit from dose of northern exposure

While City investors and Westminister politicians have been weighing a Pfizer bid for AstraZeneca, a very different attempt to capitalise on UK scientific research has launched in the north of England.

Examples of these include: Immunodiagnostic Systems, which is quoted on London’s Alternative Investment Market and has a market capitalisation of £150m; Reinnervate, a 3D cell culture specialist; Glythera, a biotechnology company; and Orla Proteins, which engineers proteins and antibodies.

Please read the full article – Financial Times